Lexaria Bioscience (Lexaria Bioscience) EPS (Basic) : $-0.68 (TTM As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience EPS (Basic)?

Lexaria Bioscience's basic earnings per share (Basic EPS) for the three months ended in Feb. 2024 was $-0.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.68.

Lexaria Bioscience's EPS (Diluted) for the three months ended in Feb. 2024 was $-0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.68.

Lexaria Bioscience's EPS without NRI for the three months ended in Feb. 2024 was $-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2024 was -0.68.

During the past 3 years, the average EPS without NRI Growth Rate was 12.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 15.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -4.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Lexaria Bioscience's highest 3-Year average EPS without NRI Growth Rate was 42.00% per year. The lowest was -69.00% per year. And the median was 0.60% per year.

Lexaria Bioscience EPS (Basic) Historical Data

The historical data trend for Lexaria Bioscience's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience EPS (Basic) Chart

Lexaria Bioscience Annual Data

Trend

Oct13

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

EPS (Basic)

Get a 7-Day Free Trial

-1.50

-1.47

-0.95

-1.24

-1.01

Lexaria Bioscience Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EPS (Basic)	Get a 7-Day Free Trial															-0.22	-0.37	-0.12	-0.13	-0.06

Lexaria Bioscience EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lexaria Bioscience's Basic EPS for the fiscal year that ended in Aug. 2023 is calculated as

Basic EPS (A: Aug. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.665	-	0)	/	6.614
	=	-1.01

Lexaria Bioscience's Basic EPS for the quarter that ended in Feb. 2024 is calculated as

Basic EPS (Q: Feb. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.65	-	0)	/	10.765
	=	-0.06

EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68

Lexaria Bioscience (NAS:LEXX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lexaria Bioscience EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.

Executives

Catherine C. Turkel	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey	officer: Chief Financial Officer	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka	director, 10 percent owner, officer: CEO	1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle	officer: Secretary	100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr	director
Brian W. Quigley	director	100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie	director	305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger	officer: CFO	8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty	director, 10 percent owner	23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar	director, officer: CFO	604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter	director	220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford	director	888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke	officer: Sr. VP, Business Development	38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini	director, 10 percent owner	11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan	director, officer: Vice President - Corp Develop	SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6